Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating income | -$9.63M | $5.27M | -$7.24M | -$7.24M | -$9.09M | -$11.4M | -$13.3M | -$9.86M | -$11.6M | -$14.7M |
| Net income | -$9.66M | -$7.59M | -$7.26M | -$7.25M | -$9.17M | -$11.3M | -$13.2M | -$10.7M | -$11.4M | -$13.1M |
| EPS (diluted) | $0.40 | -$2.76 | -$2.41 | -$1.70 | -$1.29 | -$1.59 | -$1.81 | -$1.05 | -$0.73 | -$0.29 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$786K | -$4.86M | -$5.31M | -$6.45M | -$7.25M | -$9.35M | -$11.5M | -$8.53M | -$8.83M | -$13.0M |
| Capital expenditures | $25.0K | $58.0K | $223K | $216K | $91.0K | $69.0K | $84.0K | $33.0K | $25.0K | $60.0K |
| Free cash flow | -$811K | -$4.91M | -$5.53M | -$6.67M | -$7.34M | -$9.42M | -$11.6M | -$8.57M | -$8.85M | -$13.1M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $2.71M | $10.8M | $5.24M | $28.8M | $19.6M | $13.5M | $2.44M | $2.47M | $3.11M | $3.91M |
| Total assets | $3.37M | $11.0M | $6.09M | $37.1M | $26.3M | $16.8M | $9.54M | $8.33M | $6.03M | $81.5M |
| Total liabilities | $1.17M | $556K | $4.76M | $5.59M | $1.97M | $2.39M | $2.25M | $3.83M | $2.50M | $3.99M |
| Shareholders' equity | $1.70M | $9.99M | $1.33M | $31.5M | $24.3M | $14.4M | $7.29M | $4.50M | $3.53M | $77.6M |
| Retained earnings | -$13.0M | -$20.6M | -$27.9M | -$35.1M | -$44.3M | -$55.6M | -$68.8M | -$79.5M | -$90.9M | -$104M |
| Shares (wtd avg diluted) | 15.8M | 2.01M | 3.01M | 7.19M | 7.11M | 7.11M | 7.26M | 10.2M | 15.6M | 45.8M |
Every figure is extracted from Microbot Medical Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.